Literature DB >> 18022577

A scheme for defining cause of death and its application in the T cell depletion trial.

Edward Copelan1, James T Casper, Shelly L Carter, Jo-Anne H van Burik, David Hurd, Adam M Mendizabal, John E Wagner, Saul Yanovich, Nancy A Kernan.   

Abstract

The primary cause of death (COD) provides important information in many studies of hematopoietic stem cell transplantation (HSCT). A panel of experts critically assessed the CODs submitted by 15 transplantation centers for 281 patients who died in a randomized multicenter trial of unrelated HSCT. The panel reviewed the CODs reported by the transplantation centers, which used the Center for International Blood and Marrow Transplant Research and National Marrow Donor Program COD reporting form. The panel determined that the existing criteria for primary and contributing CODs lacked sufficient stringency for uniform interpretation. A hierarchy was developed and applied to the T cell depletion project. Using its scheme, the panel reclassified 157 CODs (56%) reported by the transplantation centers. The changes resulted in increased recognition of graft-versus-host disease as the primary COD and a concomitant decrease in attribution of the primary COD to infection. This algorithm promotes consistent assignment of primary and contributing CODs for patients with leukemia or lymphoma who expire after myeloablative allogeneic HSCT.

Entities:  

Mesh:

Year:  2007        PMID: 18022577     DOI: 10.1016/j.bbmt.2007.08.047

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  64 in total

1.  Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.

Authors:  Jo-Anne H Young; Brent R Logan; Juan Wu; John R Wingard; Daniel J Weisdorf; Cathryn Mudrick; Kristin Knust; Mary M Horowitz; Dennis L Confer; Erik R Dubberke; Steven A Pergam; Francisco M Marty; Lynne M Strasfeld; Janice Wes M Brown; Amelia A Langston; Mindy G Schuster; Daniel R Kaul; Stanley I Martin; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-25       Impact factor: 5.742

2.  A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Authors:  Barbara Spitzer; Ann A Jakubowski; Esperanza B Papadopoulos; Kirsten Fuller; Patrick D Hilden; James W Young; Juliet N Barker; Guenther Koehne; Miguel-Angel Perales; Katharine C Hsu; Marcel R van den Brink; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Hugo Castro-Malaspina; Richard J O'Reilly; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-12       Impact factor: 5.742

Review 3.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

4.  Autopsy among recipients of stem cell transplant for hematologic malignancies in the modern era.

Authors:  Eva Medvedova; Lynne Strasfeld; Peter Stenzel; Richard T Maziarz
Journal:  Bone Marrow Transplant       Date:  2020-07-08       Impact factor: 5.483

5.  The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

Authors:  Joshua A Hill; Bryan T Mayer; Hu Xie; Wendy M Leisenring; Meei-Li Huang; Terry Stevens-Ayers; Filippo Milano; Colleen Delaney; Mohamed L Sorror; Brenda M Sandmaier; Garrett Nichols; Danielle M Zerr; Keith R Jerome; Joshua T Schiffer; Michael Boeckh
Journal:  Blood       Date:  2017-02-16       Impact factor: 22.113

6.  CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Authors:  Roni Tamari; Stephen S Chung; Esperanza B Papadopoulos; Ann A Jakubowski; Patrick Hilden; Sean M Devlin; Jenna D Goldberg; Miguel-Angel Perales; Doris M Ponce; Craig S Sauter; Molly A Maloy; Dara Y Herman; Virginia Klimek; James W Young; Richard J O'Reilly; Sergio A Giralt; Hugo Castro-Malaspina
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

7.  A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Authors:  Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina
Journal:  Leuk Lymphoma       Date:  2014-03-20

8.  Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Juan Carlos Hernández-Boluda; Arturo Pereira; Nicolaus Kröger; Dietrich Beelen; Marie Robin; Martin Bornhäuser; Emanuele Angelucci; Antonin Vitek; Igor Wolfgang Blau; Riitta Niittyvuopio; Jürgen Finke; Jan J Cornelissen; Jakob Passweg; Peter Dreger; Eefke Petersen; Lothar Kanz; Jaime Sanz; Tsila Zuckerman; Nienke Zinger; Simona Iacobelli; Patrick Hayden; Tomasz Czerw; Donal McLornan; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2020-04-14       Impact factor: 11.528

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.

Authors:  Marcel R M van den Brink; Robert R Jenq; Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Enrico Velardi; Jennifer J Tsai; Ann E Slingerland; Odette M Smith; Lauren F Young; Jyotsna Gupta; Sophia R Lieberman; Hillary V Jay; Katya F Ahr; Kori A Porosnicu Rodriguez; Ke Xu; Marco Calarfiore; Hendrik Poeck; Silvia Caballero; Sean M Devlin; Franck Rapaport; Jarrod A Dudakov; Alan M Hanash; Boglarka Gyurkocza; George F Murphy; Camilla Gomes; Chen Liu; Eli L Moss; Shannon B Falconer; Ami S Bhatt; Ying Taur; Eric G Pamer
Journal:  Sci Transl Med       Date:  2016-05-18       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.